Pharmaceutical composition and method for the transdermal...

A - Human Necessities – 61 – F

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61F 13/00 (2006.01) A61K 9/127 (2006.01) A61K 33/10 (2006.01)

Patent

CA 2554860

The present invention relates to a method and transdermal pharmaceutical composition for preventing magnesium deficiency or imbalances associated with magnesium deficiency including diabetes, hypertension, high cholesterol, cardiac arrhythmias, acute myocardial infarction, arteriosclerosis, atherosclerosis, preeclampsia, dysautonomia, mitral valve prolapse, asthma, constipation, irritable bowel syndrome, migraines, muscle spasms and cramping, premenstrual syndrome, osteoporosis, kidney stones, chronic fatigue syndrome, and fibromyalgia. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of magnesium and a pharmaceutically acceptable carrier. A therapeutically effective amount of a pharmaceutically acceptable salt of zinc a vitamin such as B-complex vitamin, a carotenoid, a mineral, or a combination thereof may also be included in the transdermal pharmaceutical composition. A therapeutically effective amount of progesterone may also be included in the transdermal pharmaceutical composition. The transdermal pharmaceutical composition may be topically administered to prevent magnesium deficiency or imbalances caused by magnesium deficiency.

La présente invention concerne un procédé et une composition pharmaceutique transdermique destinée à prévenir la carence en magnésium ou les déséquilibres associés à la carence en magnésium, y compris le diabète, l'hypertension, le taux de cholestérol élevé, l'arythmie cardiaque, l'infarctus aigu du myocarde, l'arteriosclérose, l'athérosclérose, la préeclampsie, la dysautonomie, le prolapsus de la valve mitrale, l'asthme, la constipation, le syndrome des intestins irritables, les migraines, les spasmes et les crampes musculaires, le syndrome prémenstruel, l'ostéoporose, les calculs rénaux, le syndrome de fatigue chronique, et la fibromyalgie. La composition pharmaceutique transdermique comprend une quantité efficace d'un sel pharmaceutiquement acceptable de magnésium et un excipient pharmaceutiquement acceptable. Une quantité therapeutiquement efficace d'un sel pharmaceutiquement acceptable de zinc, une vitamine telle que la vitamine du complexe B, un caroténoïde, un minéral ou leur combinaison peuvent aussi être inclus dans la composition pharmaceutique transdermique. Une quantité thérapeutiquement efficace de progestérone peut aussi être incluse dans la composition pharmaceutique transdermique. La composition pharmaceutique transdermique peut être administrée topiquement pour prévenir la carence en magnésium ou les déséquilibres associés à la carence en magnésium.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Pharmaceutical composition and method for the transdermal... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical composition and method for the transdermal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition and method for the transdermal... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1696922

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.